Zydus' US subsidiary acquires speciality drug asset in US

Under the terms of the agreement, Sentynl will acquire global rights to Nulibry and will be responsible for the ongoing development and commercialisation of Nulibry in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/15RyrzU
via IFTTT